SGS Attains Biosafety Level 2 Compliance at Fairfield, NJ Facility

September 10, 2015
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management
Volume 11, Issue 10

SGS Life Science Services announced that its facility in Fairfield, NJ, has been upgraded to be Biosafety Level 2 (BSL-2) compliant, according to the Centers for Disease Control and Prevention (CDC) guidelines.

SGS Life Science Services, the bio/pharmaceutical analytical and bioanalytical contract solutions provider, announced that its facility in Fairfield, NJ, has been upgraded to be Biosafety Level 2 (BSL-2) compliant, according to the Centers for Disease Control and Prevention (CDC) guidelines. SGS has made significant investment in facilities and staff training to handle virulent organisms for the purposes of microbiological testing, chemical and raw-material testing, and stability testing of pharmaceutical materials.

With the enhanced containment capabilities, the facility is now able to support the development programs of biotech and pharmaceutical companies involved in vaccines against pathogens such as Poliovirus, Rotavirus, Influenza A, and Hepatitis A, B and C, also drugs against resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus (MRSA), NDM-1 Escherichia coli, and Clostridium difficile.

SGS has seen an increase in demand for services from bio/pharmaceutical development companies, medical device manufacturers, and also environmental monitoring companies interested in such pathogens covered by the CDC guidelines, such as Legionella and Burkholderia cepacia. The range of products SGS can now work with at the Fairfield laboratory include both animal and human-derived samples such as blood (including serum, antibodies, and phagocytes) and tissue. 

This upgrade and investment comes three years after the Fairfield facility underwent a large scale expansion, doubling its footprint to 30,000 square feet. With 18 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides clinical trial management (Phase I to IV), and services encompassing data management and statistics, PK/PD modelling and simulation, pharmacovigilance and regulatory consultancy.

Source: SGS